Company press releases

Displaying 51 - 100 of 109 results
Released Company Title Industry Topic
20 Jun 2023
07:00 CEST 		ARGENX SE argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy 20103010 Biotechnology Other subject
31 May 2023
07:00 CEST 		ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
04 May 2023
07:00 CEST 		ARGENX SE argenx Reports First Quarter 2023 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
03 May 2023
22:01 CEST 		ARGENX SE argenx announces results of Annual General Meeting of Shareholders 20103010 Biotechnology Other subject
02 May 2023
07:00 CEST 		ARGENX SE argenx to Present at BofA Securities 2023 Health Care Conference 20103010 Biotechnology Other subject
27 Apr 2023
07:00 CEST 		ARGENX SE argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023 20103010 Biotechnology Other subject
18 Apr 2023
07:00 CEST 		ARGENX SE argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting 20103010 Biotechnology Other subject
17 Apr 2023
08:00 CEST 		ARGENX SE argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology 20103010 Biotechnology Other subject
17 Mar 2023
21:01 CET 		ARGENX SE argenx Announces Annual General Meeting of Shareholders on May 2, 2023 20103010 Biotechnology Other subject
15 Mar 2023
14:25 CET 		ARGENX SE argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
02 Mar 2023
07:00 CET 		ARGENX SE argenx Announces Planned Transition of Chief Operating Officer 20103010 Biotechnology Other subject
02 Mar 2023
07:00 CET 		ARGENX SE argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update 20103010 Biotechnology Other subject
27 Feb 2023
22:01 CET 		ARGENX SE argenx Appoints Steve Krognes to Board of Directors 20103010 Biotechnology Other subject
27 Feb 2023
07:00 CET 		ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
23 Feb 2023
07:00 CET 		ARGENX SE argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023 20103010 Biotechnology Other subject
27 Jan 2023
07:00 CET 		ARGENX SE argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod 20103010 Biotechnology Other subject
16 Jan 2023
19:30 CET 		ARGENX SE argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director 20103010 Biotechnology Other subject
09 Jan 2023
07:00 CET 		ARGENX SE argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline 20103010 Biotechnology Other subject
03 Jan 2023
07:00 CET 		ARGENX SE argenx to Present at 41st Annual J.P. Morgan Healthcare Conference 20103010 Biotechnology Other subject
12 Dec 2022
22:01 CET 		ARGENX SE argenx Appoints Ana Cespedes to Board of Directors 20103010 Biotechnology Other subject
10 Dec 2022
17:30 CET 		ARGENX SE argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia 20103010 Biotechnology Other subject
30 Nov 2022
07:00 CET 		ARGENX SE argenx Enters Into Agreement To Acquire Priority Review Voucher 20103010 Biotechnology Other subject
22 Nov 2022
07:00 CET 		ARGENX SE argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review 20103010 Biotechnology Other subject
07 Nov 2022
07:00 CET 		ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
27 Oct 2022
07:00 CEST 		ARGENX SE argenx Reports Third Quarter 2022 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
20 Oct 2022
07:00 CEST 		ARGENX SE argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022 20103010 Biotechnology Other subject
21 Sep 2022
07:00 CEST 		ARGENX SE argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings 20103010 Biotechnology Other subject
21 Sep 2022
07:00 CEST 		ARGENX SE argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
08 Sep 2022
20:10 CEST 		ARGENX SE argenx Appoints Camilla Sylvest to Board of Directors 20103010 Biotechnology Other subject
31 Aug 2022
07:00 CEST 		ARGENX SE argenx to Present at Wells Fargo Healthcare Conference 20103010 Biotechnology Other subject
11 Aug 2022
13:00 CEST 		ARGENX SE argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
28 Jul 2022
08:30 CEST 		ARGENX SE argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022 20103010 Biotechnology Other subject
28 Jul 2022
07:00 CEST 		ARGENX SE argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update 20103010 Biotechnology Other subject
21 Jul 2022
07:00 CEST 		ARGENX SE argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022 20103010 Biotechnology Other subject
24 Jun 2022
07:00 CEST 		ARGENX SE argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe 20103010 Biotechnology Other subject
01 Jun 2022
07:00 CEST 		ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
31 May 2022
07:00 CEST 		ARGENX SE argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
19 May 2022
13:00 CEST 		ARGENX SE argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases 20103010 Biotechnology Other subject
10 May 2022
23:30 CEST 		ARGENX SE argenx announces results of Annual General Meeting of Shareholders 20103010 Biotechnology Other subject
05 May 2022
07:00 CEST 		ARGENX SE argenx Reports First Quarter 2022 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
05 May 2022
07:00 CEST 		ARGENX SE argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia 20103010 Biotechnology Other subject
04 May 2022
07:00 CEST 		ARGENX SE argenx to Present at BofA Securities 2022 Healthcare Conference 20103010 Biotechnology Other subject
28 Apr 2022
07:00 CEST 		ARGENX SE argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022 20103010 Biotechnology Other subject
05 Apr 2022
07:00 CEST 		ARGENX SE argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting 20103010 Biotechnology Other subject
01 Apr 2022
07:00 CEST 		ARGENX SE argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting 20103010 Biotechnology Meetings / events
29 Mar 2022
23:00 CEST 		ARGENX SE argenx announces full exercise of underwriters’ option to purchase additional ADSs 20103010 Biotechnology Other subject
29 Mar 2022
22:30 CEST 		ARGENX SE argenx announces Annual General Meeting of Shareholders on May 10, 2022 20103010 Biotechnology Other subject
28 Mar 2022
22:30 CEST 		ARGENX SE argenx announces closing of global offering 20103010 Biotechnology Other subject
24 Mar 2022
02:00 CET 		ARGENX SE argenx raises $700 million in gross proceeds in a global offering 20103010 Biotechnology Other subject
22 Mar 2022
21:15 CET 		ARGENX SE argenx announces launch of proposed global offering 20103010 Biotechnology Other subject